Triglycerides

Reference ranges

Optimal ranges are tighter than standard lab ranges and reflect functional-medicine targets, not the populations they were derived from. Reference bands depend on sex, age, and circumstance — Juno's lab analysis layers your profile context onto the printed range when you paste a value.

Peptide relevance

Tightly coupled to recent diet and insulin sensitivity. GLP-1 agonists (tirzepatide, semaglutide) reliably lower triglycerides 15-30% in obesity/T2D trials. CJC-1295 + Ipamorelin: GH-axis activation typically lowers triglycerides via increased lipolysis and improved fasting metabolism. Tesamorelin: documented triglyceride-lowering effect in HIV-lipodystrophy trials. BPC-157 / TB-500: no documented effect. KEY CAVEAT: triglycerides require a true 12-hour fast for accurate reading — non-fasted readings can be 2-3× higher and don't reflect baseline. Recent alcohol (last 48h) elevates triglycerides substantially.

Peptides that influence this marker

Documented to affect this marker. Click through for the full evidence-tiered profile.

• CJC-1295
  GHRH analog

  GH-axis activation lowers triglycerides via increased lipolysis

• Ipamorelin
  GHRP / ghrelin mimetic

  GH-axis activation lowers triglycerides via increased lipolysis

• Tier 1 — Human RCTRetatrutide↓· 12–24 weeks
  GLP-1 / GIP / glucagon triple agonist
• Tier 1 — Human RCTSemaglutide↓· 12 weeks
  GLP-1 receptor agonist

  Reliably lowers triglycerides 15-30% in T2D / obesity trials

• Tier 1 — Human RCTTesamorelin↓· 12–26 weeks
  GHRH analog

  Documented triglyceride-lowering in HIV-lipodystrophy trials

• Tier 1 — Human RCTTesamorelin / Ipamorelin↓· 12–26 weeks
  Blend

  Improves alongside VAT reduction in the Tesamorelin trials.

• Tier 1 — Human RCTTirzepatide↓· 12 weeks
  GLP-1 / GIP dual agonist

  Reliably lowers triglycerides 15-30% in T2D / obesity trials